Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz On Track To Complete Aurobindo Deal By March

As Firm Completes Acquisition Of Aspen’s Japanese Operations

Executive Summary

Sandoz says it expects to close the sale of its US dermatology and oral solids business to Aurobindo by the end of the first quarter of 2020, having seen the deal’s completion date pushed back from 2019.

You may also be interested in...



Sandoz Gains Rights To Two US Injectables

With the $1bn deal to transfer its US dermatology and orals solids operations to Aurobindo still awaiting completion, Sandoz is expanding its portfolio of sterile injectables - a key area of focus for the company - by acquiring the rights to two products from BE Pharmaceuticals.

Aspen Makes Multiple Moves Amid Challenging Conditions

South Africa’s Aspen has made multiple strategic moves, including divesting its Japanese business to Sandoz and selling its local Phekolong Pharmaceuticals South African subsidiary to Laurus Labs, as part of efforts to better position itself in the face of “challenging” market conditions.

FDA Gives Then Rescinds Clearance For Aurobindo Plant

Aurobindo Pharma shares have nosedived after the US Food and Drug Administration said an investigation into one of the Indian drugmaker’s plants was still open, days after issuing a notice giving the site the all-clear.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB149573

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel